SMARCA2 and neoplasm: Despite no changesin tumor growth in the SCLC-A xenografts, immunoblotting and IHC analysis oftumors confirmed on-target drug activity of AU-24118 as indicated by efficientloss of SMARCA4, SMARCA2, and PBRM1 (Figures3C and S3K).